Skip to main content
  • Research article
  • Open access
  • Published:

Cross-talks between gut microbiota and tobacco smoking: a two-sample Mendelian randomization study



Considerable evidence has been reported that tobacco use could cause alterations in gut microbiota composition. The microbiota-gut–brain axis also in turn hinted at a possible contribution of the gut microbiota to smoking. However, population-level studies with a higher evidence level for causality are lacking.


This study utilized the summary-level data of respective genome-wide association study (GWAS) for 211 gut microbial taxa and five smoking phenotypes to reveal the causal association between the gut microbiota and tobacco smoking. Two-sample bidirectional Mendelian randomization (MR) design was deployed and comprehensively sensitive analyses were followed to validate the robustness of results. We further performed multivariable MR to evaluate the effect of neurotransmitter-associated metabolites on observed associations.


Our univariable MR results confirmed the effects of smoking on three taxa (Intestinimonas, Catenibacterium, and Ruminococcaceae, observed from previous studies) with boosted evidence level and identified another 13 taxa which may be causally affected by tobacco smoking. As for the other direction, we revealed that smoking behaviors could be potential consequence of specific taxa abundance. Combining with existing observational evidence, we provided novel insights regarding a positive feedback loop of smoking through Actinobacteria and indicated a potential mechanism for the link between parental smoking and early smoking initiation of their children driven by Bifidobacterium. The multivariable MR results suggested that neurotransmitter-associated metabolites (tryptophan and tyrosine, also supported by previous studies) probably played a role in the action pathway from the gut microbiota to smoking, especially for Actinobacteria and Peptococcus.


In summary, the current study suggested the role of the specific gut microbes on the risk for cigarette smoking (likely involving alterations in metabolites) and in turn smoking on specific gut microbes. Our findings highlighted the hazards of tobacco use for gut flora dysbiosis and shed light on the potential role of specific gut microbiota for smoking behaviors.

Peer Review reports


Cigarette smoking, a major public health threat across the world, causes more than 8 million deaths globally each year. Despite higher awareness of cigarettes’ adverse effects and ongoing efforts on tobacco control, there still exist 22.3% of the global population being regular smokers (made up of 36.7% of the world’s men and 7.8% of all women) [1]. Smoking is highly inherited with an estimated heritability of 44% (66% for males and 21% for females, respectively) [2, 3] and meanwhile is influenced by postnatal environmental conditions (e.g., socioeconomic position, culture). Understanding the modifiable risk factors of smoking as well as its full spectrum of consequence is always an essential and challenging question, especially at the microscale and molecular levels. The term “gut microbiota” refers to all microorganisms that inhabit the human gastrointestinal tract, whose volume reaches trillion level [4]. Due to its intricate and reciprocal symbiotic relationship with the host, the gut microbiota is closely related to human health, not just intestinal diseases [5,6,7]. The diversity and quantity of intestinal microbiome are in a dynamic balance, which might be disturbed by various factors, such as genetics, aging, living habits, as well as environmental factors (e.g., cigarette smoke exposure) [8, 9]. Indeed, mounting observational evidence has reported that tobacco use was associated with alterations in the gut microbiota composition [10,11,12]. Taking Bifidobacterium (the representative bacteria of probiotics) for example, existing population studies unanimously found that the abundance of Bifidobacterium was significantly decreased in current smokers compared with non-smokers, regardless of the ethnicities [13,14,15,16,17]. Instead, smoking cessation, even for short periods, could somewhat restore Bifidobacterium abundance [15]. In vivo and in vitro studies [18, 19] also supported the inhibitory effect of cigarette smoke on the growth of Bifidobacterium. However, population-level studies with higher evidence levels for causality are lacking.

Given the essential role of the gut microbiota in the regulation of the central nervous system (CNS) [20], another interesting question is whether smoking behaviors are affected by the gut microbiota. Currently, the microbiota-gut–brain axis, i.e., gut microbiota changes may alter brain function, piqued significant research interest [21]. A recent review summarized the evidence for the presence of bidirectional communications of the axis, and such crosstalk has been linked to major depressive disorder and other psychiatric disorders [22]. Another recent study also identified that abundant genetic signals associated with the gut microbiome were enriched in the genes of neurological functions [23]. In the meantime, the neurological function of the brain was further closely related to tobacco use. Two brain areas, the orbitofrontal cortex and the prefrontal cortex, could interact to turn nicotine cravings on or off [24, 25]. The dopamine reward circuit in the limbic system of the brain was a widely accepted mechanism of tobacco use that withdrawal from nicotine, the main component of cigarettes, will cause a drastic decrease in dopamine secretion. Moreover, animal studies have directly shown that altering the gut microbiome could affect the reward- and stress-related behavior associated with substance abuse, including tobacco [26,27,28]. Therefore, the gut microbiota has the possibility to affect smoking though the pathways of microbiota-gut-brain-smoking and on the contrary gut microbial homeostasis could be a potential target for addressing tobacco use via improving brain functions [29]. However, the direct links from the microbiome to smoking behaviors which concordance with the gut-brain axis were largely unexplored.

Meanwhile, prior evidence has been found that the manner of communication between the microbiota and the brain involves autonomic nervous system with corresponding neurotransmitters (e.g., γ-aminobutyric acid (GABA), endorphins), bacterial metabolites (typically, short-chain fatty acids) [21], etc. Amino acid metabolites and amino acid-related derivatives are essential sources of most important neurotransmitters. Therefore, associations between the microbiome and smoking could be bridged by relevant metabolites, such as tryptophan (the raw material for serotonin, as known as 5-hydroxytryptamine, 5HT).

Mendelian randomization (MR) is an increasingly used approach to integrate summary data of genome-wide association study (GWAS) to identify causal links between exposures and outcomes. The main reason for its advantage in inferring causality is that MR employs the genetic variants as instrumental variables. MR uses the facts that (1) genetic variants are randomly inherit one allele from each of the father and mother (namely the law of segregation assortment) and (2) alleles will be passed to offspring independently of each other (namely the law of independent assortment). Therefore, MR results are unlikely to be influenced by the environment that might confound the estimated relationship. Recently, the MiBioGen consortium [30] released numerous microbiome abundance-associated loci, offering an unprecedented chance to explore the causality between the gut microbiota and tobacco use. Based on the knowledge above, we hypothesized that the gut microbiome links smoking behaviors and conducted a two-sample bi-directional MR analysis to elucidate the causal association between the gut microbiota and smoking phenotypes and further explore the potential role of several metabolites on these associations.


An overview of the analytical plan is shown in Additional file 1: Figure S1.

Data sources and instrumental variable selection

The data analyzed in this secondary study is publicly available from existing, published GWASs and therefore the ethical approval and informed consent have been obtained by all original studies (Table 1). Detailed information, such as recruitment criteria of population and quality control of genetic data, can be found in the original paper (Table 1). The source data and its related papers were found on PubMed and acquired easily on GWAS Catalog ( The search terms for summary statistics of gut microbes on PubMed was “gut microbiota” and “genome-wide association study”. The specific terms of smoking phenotypes and metabolites, for example smoking initiation or tryptophan, were directly used to found summary statistics on GWAS Catalog. These GWAS sample populations needed to be predominantly of European descent and largely independent of each other.

Table 1 Characteristics of data in this study

The genetic instrument variables (IVs), typically single-nucleotide polymorphisms (SNPs), for the gut microbiota were retrieved from a large-scale GWAS meta-analysis, which contained 18,340 European-dominated participants from 24 separate cohorts with 5,717,754 SNPs after imputation [31, 32]. In the original study, the gut microbiota was categorized into 257 taxa at six taxonomic levels: phylum [p], class [c], order [o], family [f], and genus [g]. Of these, 211 taxa (9 phyla, 16 classes, 20 orders, 35 families, and 131 genera), which were eligible for the mbQTL (microbial quantitative trait locus) mapping analysis, were included in this study. The effect sizes of smoking-related SNPs were acquired from a meta-analyzed GWAS summary association data from 1,232,091 individuals with predominantly European ancestry [30, 33], including age of smoking initiation (a continuous phenotype), smoking initiation (a binary phenotype, ever being a regular smoker), cigarettes per day (a continuous indicator of smoking heaviness), and smoking cessation (a binary phenotype, contrasting current versus former smokers). Of note, lifetime smoking was also included as a comprehensive phenotype, using data from the UK Biobank which recruited 462,690 European ancestry dominated samples [34, 35]. The lifetime smoking is a continuous composite concept of the burden of lifetime exposure to smoking constructed by smoking initiation/cessation, smoking heaviness, and smoking duration.

Furthermore, we also sought to explore the potential role of neurotransmitters in the biological pathway of the microbiota to smoking. After a systematic literature search in PubMed (we only considered the metabolites whose serum levels were commonly measured in regular metabolomic studies), we identified several important neurotransmitter-associated metabolites (including tryptophan, tyrosine, phenylalanine, glutamate, glycine) that may closely relate to brain function, especially substance use disorder, which subsequently affect smoking [36,37,38,39]. In addition, we also considered an important group of bacterial metabolites (i.e., short-chain fatty acids). We extracted genetic data for these specific human blood metabolites (i.e., tryptophan, tyrosine, phenylalanine, glutamate, glycine, and valerate) from a GWAS comprising 7824 European adult individuals [40, 41]. Specifically, tryptophan, tyrosine, phenylalanine, and glutamate are closely related to neurotransmitters, respectively, 5-HT, dopamine, endorphins, and GABA. Glycine itself is a kind of neurotransmitter [42]. Valerate belongs to the short-chain fatty acids, which could regulate the blood–brain barrier, myelin formation, vagal excitability, and microglia maturation [43].

The selection of IVs, the key to ensure the accuracy and robustness of the causal inferences, should meet MR’s three key assumptions (Fig. 1). Then, the following steps were performed. Firstly, palindromic variants with minor allele frequency greater than 0.4 were excluded; secondly, variants and their alleles were harmonized between the GWAS results of exposure and outcome; thirdly, independent SNPs (LD r2 < 0.01 and clumping distance = 250 kb, based on the European-based 1000 Genome Projects reference panel) were selected at a compromised significant level (1 × 10−6) due to the relatively small sample size for mbQTL identification. To mitigate the effect of weak IV bias, the regular genome-wide significance (5 × 10−8) was retained as a sensitivity analysis.

Fig. 1
figure 1

Schematic representation of the a two-sample bi-directional Mendelian randomization analysis and b multivariable Mendelian randomization analysis. MR was used to evaluate the causal links between 211 microbial taxa and five smoking phenotypes with or without considering neurotransmitter-associated or bacterial metabolites. Three key assumptions of MR: (1) genetic variants must be associated with exposures, (2) genetic variants must not be associated with confounders, and (3) genetic variants must affect outcomes only through exposures, not through other pathways

The usage and interpretation of our MR study adhere to the STROBE-MR (Strengthening the Reporting of Observational Studies in Epidemiology-Mendelian Randomization) checklist [44] (Additional file 1: Table S1) and the critical appraisal checklist proposed by Davies et al. [45] (Additional file 1: Table S2).

Statistical analysis

The two-sample MR study was incorporated to evaluate the causal links between 211 microbial taxa and five smoking phenotypes. The list of covariates varies between original GWASs, but always included sex and age. The details can be found in the original studies. Causal effects were estimated by five high-efficiency methodologies: the multiplicative random-effects model for the inverse-variance weighted (IVW) method (as the main MR method) [46], a constrained maximum likelihood and model averaging-based MR method (cML-MA, also as the main MR method) [47], weighted median method (sensitivity analysis) [48], MR-Egger regression (sensitivity analysis) [49], and MR pleiotropy residual sum and outlier (MR-PRESSO) method (sensitivity analysis) [50]. Different approaches yield valid evidence under different assumptions. cML-MA, which without relying on the InSIDE assumption, was also applied as a complementary method in our study to control correlated and uncorrelated pleiotropic effects [47]. In addition, the Cochran’s Q test in IVW was adopted to test the heterogeneity among SNPs included in each analysis. The intercept from MR-Egger method was used to assess the Instrument Strength Independent of Direct Effect (InSIDE) assumption which assumes that the horizontal pleiotropic effects are independent of the variant-exposure associations. Pintercept < 0.05 suggests the existence of horizontal pleiotropy. MR-PRESSO global test was also used to evaluate overall horizontal pleiotropy. Meanwhile, MR-PRESSO corrected for horizontal pleiotropy by outlier removal. The above series of analyses was repeated to explore the causality in the other way, i.e., the impacts of tobacco use on gut microbial composition. Finally, as an attempt to uncover possible vertical pleiotropic pathways that could arise from specific serum metabolites, the multivariable MR analyses including MVMR-IVW and MVMR-Egger were performed to estimate the causal effect of specific gut microbes on smoking after adjusting for six neurotransmitter-associated or bacterial metabolites simultaneously and separately. Parameter setting was the same as for univariate MR.

MR analyses were performed using the “TwoSampleMR” (version 0.5.6), “MRcML” (version, and “MendelianRandomization” (version 0.6.0) packages in R (version 4.1.2) [50, 51]. The statistical significance of the MR effect estimate was defined as a false discovery rate (FDR) of < 10%, where the Benjamini–Hochberg procedure was used to correct for the number of taxa tested, accounting for multiple comparisons.


Causal effect of smoking on gut microbiota

To understand the consequences of smoking behaviors (including smoking initiation, cigarette per day, age of initiation, smoking cessation, and lifetime smoking) on the abundance of the gut microbiome, two-sample MR tests were performed. We tested the potential causality from smoking-related traits to all available gut taxa. Detailed significant results for the causal relationship from smoking phenotypes to gut microbial taxa are shown in Table 2.

Table 2 Significant MR results of causal links between gut microbiome and smoking phenotypes by using IVW method and cML-MA method

The results of IVW analyses showed that the genetic liability for smoking initiation had a causal contribution to an increased abundance of Intestinimonas[g] (Beta ± SE: 0.265 ± 0.090, P = 3.15e − 03), which was in line with the evidence from a mice model showing that exposure to the major cigarette smoke carcinogens (NNK plus BaP) could elevate fecal level of Intestinimonas [52] (Fig. 2a). We also found that increased genetically predicted lifetime smoking was significantly related to higher abundance of Catenibacterium[g] (Beta ± SE: 0.505 ± 0.170, P = 2.98e − 03) as well as lower abundance of RuminococcaceaeNK4A214[g] (Beta ± SE: − 0.261 ± 0.074, P = 4.48e − 04) and RuminococcaceaeUCG005[g] (Beta ± SE: − 0.237 ± 0.076, P = 1.91e − 03), corroborating previous observational findings from two cross-sectional studies based on a Bangladeshi population [53] and a Chinese population [54], respectively (Fig. 2b,c). The MR results also suggested that smoking initiation was causally associated with the abundance of Pasteurellales[o] (Beta ± SE: − 0.328 ± 0.097, P = 7.40e − 04), Pasteurellaceae[f] (Beta ± SE: − 0.328 ± 0.097, P = 7.40e − 04), Christensenellaceae[f] (Beta ± SE: − 0.278 ± 0.072, P = 1.18e − 04), ChristensenellaceaeR[g] (Beta ± SE: − 0.267 ± 0.073, P = 2.75e − 04), and Romboutsia[g] (Beta ± SE: − 0.279 ± 0.085, P = 1.06e − 03). A higher genetically predicted age of smoking initiation was causally related to a higher abundance of Lactococcus[g] (Beta ± SE: 1.135 ± 0.317, P = 3.45e − 04), but a lower abundance of Eisenbergiella[g] (Beta ± SE: − 1.062 ± 0.250, P = 2.21e − 05). Neither horizontal pleiotropy nor heterogeneity (among IVs) was detected at statistically significant levels (all P for Egger intercept > 0.05, most of the P for PRESSSO global test > 0.05, and all P for Cochran’s Q > 0.05). The results estimated by cML-MA method was highly consistent with the estimates using IVW. The FDR adjusted P-value and the family-wised corrected P-value could be found in Additional file 2: Table S4.

Fig. 2
figure 2

The summary of the key findings in the univariable MR study. Combining with existing evidence, we consistently found the causal effect of smoking on a Intestinimonas, b Catenibacterium, c Ruminococcaceae, and provided novel insights regarding d the reward loop of smoking heaviness, e the influence of parental smoking on childhood smoking. Black solid arrows indicate known evidence, red solid arrows indicate what we found in this study, and red dashed arrow indicates potentially deducible conclusion

Causal effect of gut microbiota on smoking

The original GWAS involving 18,340 individuals from 24 cohorts provided summary statistics for 211 microbial taxa. Of them, 41 taxa providing greater than or equal to three IVs were included in this MR for testing the potential causal effect of the gut microbiome on smoking behaviors (40 taxa for lifetime smoking). Estimated by IVW test, six taxa were identified, after FDR correction, to reach a statistical significance. Concordant results were observed using cML-MA method (shown in Table 2).

The MR analysis revealed that the abundance of Actinobacteria[p] (Beta ± SE: − 0.066 ± 0.024, P = 5.31e − 03), Actinobacteria[c] (Beta ± SE: − 0.053 ± 0.018, P = 3.70e − 03), Bifidobacteriales[o] (Beta ± SE: − 0.048 ± 0.019, P = 1.12e − 02), Bifidobacteriaceae[f] (Beta ± SE: − 0.048 ± 0.019, P = 1.12e − 02), and Bifidobacterium[g] (Beta ± SE: − 0.048 ± 0.018, P = 8.83e − 03) were negatively associated with the number of cigarettes smoked per day. Increased abundance of Actinobacteria[p] (Beta ± SE: 0.051 ± 0.019, P = 7.74e − 03), Bifidobacteriales[o] (Beta ± SE: 0.050 ± 0.016, P = 1.73e − 03), Bifidobacteriaceae[f] (Beta ± SE: 0.050 ± 0.016, P = 1.73e − 03), and Bifidobacterium[g] (Beta ± SE: 0.049 ± 0.016, P = 1.79e − 03) lead to later smoking initiation. When considering lifetime smoking as an outcome, the results showed a trend similar to that of cigarettes per day analysis (detailed effect estimates are shown in Table 1). The sensitivity analyses did not show clear evidence of potential horizontal pleiotropy (all P for Egger intercept > 0.05, most of the P for PRESSSO global test > 0.05). Heterogeneity was not found among SNPs (all P for Cochran’s Q > 0.05).

Another two key findings are displayed in Fig. 2d and e, indicating potential mechanisms of the gut-brain axis. All causal-effect estimates, including the sensitivity analyses, between 211 microbial taxa and five smoking phenotypes analyzed in this MR are presented in Additional file 2: Table S4. All IVs used in our study are provided in Additional file 2: Table S5. Additional visualizations of the results, including scatter plot, forest plot, and leave-one-out plot can be found in Additional file 1: Figure S2-S5. Moreover, the MR results evaluated under two instrumental variable selection thresholds (1e − 6 vs. 5e − 8) were presented in Additional file 1: Table S3, which indicated very limited difference on β-coefficients (Pearson r1e-6v.s.5e-8 = 0.99, P < 0.001).

The effect of neurotransmitter-associated metabolites on observed associations

Considering the possible contribution of serum metabolites on the progress from the gut microbiota to smoking, we used multivariable MR for observed significant associations (the results in Table 2) with six neurotransmitter-associated or bacterial metabolites (tryptophan, tyrosine, phenylalanine, glutamate, glycine, and valerate) adjusted. The multivariable MR results are reported in Table 3.

Table 3 Multivariable MR results of causal links between gut microbiome and smoking phenotypes after adjusting for specific serum metabolites

When adjusting the six metabolites together using MVMR-IVW, we found a noticeable increase in P-value for causal effect of Actinobacteria[c] (P = 0.242) and Peptococcus[g] (P = 0.502) on lifetime smoking, while the majority of results remained robust. Another change worth mentioning is that, by making rough comparisons, relatively lower β-coefficient (absolute value) for the associations between the gut microbiota and age of initiation were observed compared with the results without adjustment for the metabolites. Subsequently, focused on Actinobacteria[c] and Peptococcus[g], we implemented adjustment of one metabolite at a time. Signals of decline in significance of association were detected for tryptophan (P = 0.115 for Actinobacteria[g]; P = 0.503 for Peptococcus[g]), tyrosine (P = 0.316 for Actinobacteria[g]; P = 0.558 for Peptococcus[g]), and valerate (P = 0.218 for Peptococcus[g]). Additionally, the results of MVMR-Egger indicated that our multivariable MR estimates were unlikely biased by pleiotropy (most of P for MVMR-Egger intercept > 0.05).

The intriguing finding was presented in Fig. 3, implying the role of metabolites in the action pathway from the gut microbiota to smoking.

Fig. 3
figure 3

The summary of the key findings in the multivariable MR study. Combining with existing evidence and biological mechanisms, we consistently found that tryptophan, tyrosine, and/or valerate may take part in the action pathways from a Peptococcus and b Actinobacteria to smoking. Black solid arrows indicate known evidence, black dashed arrows indicate biological hypothesis we introduced earlier, and red dashed arrow indicates potentially deducible conclusion. The bold dashed boxes are neurotransmitters that are closely related to corresponding metabolites and are likely involved in the mechanism by which smoking responds to the gut microbiota in a metabolite-dependent manner


To our best knowledge, this work is among the first to systematically evaluate the causal relationships between the gut microbiota and tobacco use from a genetic perspective. This two-sample MR study gave reasonably strong evidence that genetically predicted abundance of specific gut microbes play non-negligible roles in the occurrence and progression of cigarette smoking, in which, metabolites may be participating. As for the other direction, the MR confirmed and strengthened the role of smoking on the gut microbiota. Leveraging the power of molecular genetic markers as instrumental variables, the MR approaches largely avoided the interference of confounders (e.g., socioeconomic position, culture) and reversed causality which make regular observational study vulnerable [45].

As mentioned in the introduction, the theory of the microbiota-gut-brain communication hints at a possible influence of the gut microbiota on smoking. Nevertheless, few studies had directly explored this theme. Leveraging the large-scale GWAS data sources, our MR study filled this knowledge gap from a novel angle. (1) Previous studies indicated that smoking would decrease the abundance of Actinobacteria while our results found that a lower abundance of Actinobacteria may cause an increase in the number of cigarettes smoked per day, i.e., worse smoking status. More severe smoking conditions may in turn cause a further diminishment in Actinobacteria abundance, implying a potential positive feedback effect [10, 55]. This might partially explain why smokers tend to increase the tobacco use. (2) In addition, observational research showed that, compared to infants from non-smoking families, those from smoking households had lower intestinal flora diversity and abundance, with Bifidobacterium in particular [56]. Interestingly, we found a lower abundance of Bifidobacterium may induce an earlier age of smoking initiation. While conventional wisdom has expounded that early smoking in children may result from early exposure to third-hand smoke or imitation of father’s smoking behavior [57, 58], our study provides new insights that the early smoking initiation may be proportionally explained by gut flora. Regulating the gut microbiota, such as probiotic intervention, might be an option to redeem bad effects caused by premature smoke exposure.

Rather than just concerning the causality between the gut microbiota and smoking, we also considered the possible involvement of metabolites in this process. (1) Our results suggested an attenuated significance of association between Peptococcus and smoking after adjusting tryptophan and/or tyrosine, implying a potential metabolite-dependent mechanism of the microbiota on smoking that these two amino acids drove. Wen’s study, from another angle that using metabolomics and 16S rRNA gene sequencing analyses in the rat model, proved the correlation between Peptococcus and key metabolic pathways, also including tryptophan metabolism and tyrosine metabolism [59]. (2) MetOrigin is a bioinformatics tool, aiming to identify which bacteria and how they participate in certain metabolic reactions [60]. A similar implication in our multivariable MR analysis that tryptophan may modify the effects of Actinobacteria on smoking was also somewhat corroborated in this platform by a simple quick search, which supported the relationship between Actinobacteria and tryptophan synthase.

There is growing evidence, albeit some indirect, providing possible biological explanations for the mechanisms of commensal gut microbiota on smoking, particularly probiotics such as Bifidobacterium. (1) The vagus nerve is thought to be a major modulatory constitutive communication pathway between the intestinal bacteria and the brain. Bifidobacterium longum have been found, via the vagus nerve, to send signals to the brain, leading to the secretion of a higher level of dopamine [61]. Since dopamine is related to the brain's reward function, higher levels of dopamine will offset the euphoria of smoking or the pain of quitting, thereby reducing smoking addiction [62]. (2) Neurotransmitters probably mediate the influences of the intestinal microbiome on smoking. For instance, Bifidobacterium was reported to promote serotonin (5-HT) biosynthesis in colonic enterochromaffin cells by activating the CGA/ADRα2A cascade signal and regulating the TRP/TPH-OR pathways [63, 64]. 5-HT has been the therapeutic target for addiction to alcohol, cocaine, or drug, so it may also be for smoking [65]. Other neurotransmitters with similar functions and previously shown to be influenced by Bifidobacterium also include GABA [66] and noradrenaline [67]. (3) The close link of metabolites (e.g., short-chain fatty acids [68], metabolite acetate [69]) or components (e.g., peptidoglycan [PGN]) of Bifidobacterium with the CNS may explain its effect on smoking. Short-chain fatty acids are relevant to the morphology and function of microglia [70], and metabolite acetate has therapeutic potential to prevent cognitive impairment [69]. PNG can penetrate the blood-brain barrier, entering the brain, and communicating with the PGN-sensing molecules (Pglyrp2) in the amygdala [71, 72]. Accordingly, changes in metabolite levels resulting from gut flora dysbiosis make an unavoidable effect on CNS, releasing fear- or anxiety-like emotions or triggering depression, subsequently elevating the risk of smoking initiation or failure to smoking cessation [73,74,75]. The above biological evidence also explains, to some extent, why the relationship between the gut microbiota and smoking may be modified after adjusting for specific amino acids or short-chain fatty acids. A point worth noting is that these potential mechanisms are not fully evidenced. In addition, there is a non-negligible gap between nicotine cravings and the complex smoking behaviors/pattern observed at the population level. Future studies on the gut microbiome and smoking behaviors are anticipated. Certainly, before moving forward, specialized mechanistic investigations are needed to understand the distinct roles of individual taxa, as most of the currently available mechanistic explanations remain at the generalized whole-gut microbial level.

In the other direction, our findings strengthened and extended existing observational evidence, suggesting that tobacco smoking could disrupt the homeostasis of the intestinal microbiota. (1) Our study supported that initiation of smoking could increase Intestinimonas abundance, which showed consistency with the results obtained in a previous experimental study. Qu and colleagues observed an elevated level of Intestinimonas after exposure to NNK plus BaP in mice [52]. Notably, NNK and BaP, the products of smoking, are the major risk elements for inducing cellular carcinogenesis of lung cancer [76]. (2) The MR results confirmed the roles of smoking for a higher abundance of Catenibacterium and a lower abundance of Ruminococcaceae which were observed from two cross-sectional studies. In a Bangladeshi population, a study exhibited that the relative abundance of Catenibacterium was significantly higher in current smokers compared with never-smokers, showing a dose-response relationship with packs of cigarettes smoked per day [53]. Enrolling 116 healthy male subjects from China, an observational study revealed that smoking could lower the abundance of Ruminococcaceae, which was independent of BMI and age [54]. Importantly, MR design allows for more reliable results with the highest evidence hierarchy other than randomized controlled trials (RCT) [45]. (3) In addition, Wang et al. reported that cigarette smoking significantly reduced the level of Lactococcus [77]. The current MR study further pointed out that the younger the year of smoking initiation, the greater this reduction. (4) Apart from the above, there also appeared several significant evidence for the effect of smoking on Eisenbergiella, Pasteurellaceae, Christensenellaceae, Haemophilus, Romboutsia, and Coriobacteriaceae, which were rarely addressed or not clearly understood before. (5) Nevertheless, it was noteworthy that for some microbial taxa, such as Bifidobacterium and Actinobacteria, the existing literature reported the impact of smoking on these taxa, while our work did not provide corresponding strong causal evidence, although most of the effect estimates were consistent in the direction. The main mechanisms by which smoking affects the gut microbiota include the following: raising the pH of the intestinal environment [18], inducing chronic low-grade inflammation or inflammation-related diseases [78], as well as promoting oxidative stress [79].

Several limitations of our study should be acknowledged. Firstly, to reduce the potential effect of weak IV bias, we applied a stricter P-value cutoff (1e − 06), compared with 1e − 05 which was used in the original paper [31] and another recent paper [80]. Thus, it may result in insufficient statistical power, a critical reason for false negatives. Because of the large number of microbial taxa, as well as the hierarchical structure (the abundance could be highly correlated for a microbial strain), and correlations among smoking phenotypes, the multiple comparison adjustment, especially global multiple corrections, may be excessive, further affecting the false negative. Therefore, causality cannot be completely ruled out in negative results, which should be treated with caution. Secondly, since the majority of participants in the GWAS of tobacco use were ancestrally Europeans, extrapolation of the results in the present study to other ethnic groups might be limited. Thirdly, although most of the participants of the gut microbial GWAS were ancestrally Europeans, the ethnic proportion was not perfectly matched between the two samples (i.e., the exposure GWAS and the outcome GWAS dataset), which may result in some levels of inconsistency in LD correlations. Fourthly, smoking is predominantly prevalent among men, and the composition of the gut microbiota also somewhat varies by gender. However, our work cannot analyze the two genders separately. Likewise, the estimates of a lifetime effect of the gut microbiota on smoking provided by MR cannot deliver much clinical meaningful for age-specific interventions. The limited sample size may also prevent us from providing a sufficiently precise estimate as well as 95% confidence intervals for clinical practice. It would be helpful to perform a gender- or age-specific MR analysis especially with larger sample size in future endeavors. Finally, the metabolites analyzed in multivariable MR were detected in human serum. We think that more appropriate and direct information may be generated from fecal samples, but unfortunately, this kind of data is currently lacking. Additionally, direct analysis of all metabolites may leave the hypothesis without sufficient biological evidence, whereas a biologically informed selection may reduce significant findings. Of a certainty, there still exist other neurotransmitters such as norepinephrine as well as other more important short-chain fatty acids such as propionate and butyrate, but the summary data of itself or its related metabolites is also lacking.


Leveraging the publicly available genetic databases, bidirectional causal links between specific intestinal microbes and cigarette smoking were identified. Taking together the existing evidence, potential mechanisms including a positive feedback loop of smoking and the potential role of neurotransmitter-associated metabolic biomarkers therein were revealed. Our study highlighted the hazards of tobacco use for gut flora dysbiosis and shed light on the potential role of specific gut microbiota for tobacco use behaviors.

Availability of data and materials

The data used in this study is freely available for download in the MiBioGen repository,, GSCAN repository,, UK Biobank repository,, and the Metabolomics GWAS repository,, respectively.

Availability of code

The actual code used to run the analyses described in this study is available at the github site at



5-Hydroxytryptamine, as known as serotonin




Body mass index


A constrained maximum likelihood and model averaging-based MR method


Central nervous system


False discovery rate


γ-Aminobutyric acid


Genome-wide association study


Instrument Strength Independent of Direct Effect


Instrument variable


Inverse-variance weighted


Linkage disequilibrium


Microbial quantitative trait locus


Mendelian randomization


MR pleiotropy residual sum and outlier


Multivariable Mendelian randomization


Nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone


PGN-sensing molecules




Randomized controlled trial


Single-nucleotide polymorphism


  1. W.H.O: Tobacco. [2022-07-28]. Accessed 28 July 2022.

  2. Vink JM, Boomsma DI. Interplay between heritability of smoking and environmental conditions? A comparison of two birth cohorts. BMC Public Health. 2011;11:316.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Vink JM, Willemsen G, Boomsma DI. Heritability of smoking initiation and nicotine dependence. Behav Genet. 2005;35(4):397–406.

    Article  PubMed  Google Scholar 

  4. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–36.

    Article  CAS  PubMed  Google Scholar 

  5. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361: k2179.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55–71.

    Article  CAS  PubMed  Google Scholar 

  7. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375(24):2369–79.

    Article  CAS  PubMed  Google Scholar 

  8. Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ. 2019;7: e7502.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Chang CS, Kao CY. Current understanding of the gut microbiota shaping mechanisms. J Biomed Sci. 2019;26(1):59.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Savin Z, Kivity S, Yonath H, Yehuda S. Smoking and the intestinal microbiome. Arch Microbiol. 2018;200(5):677–84.

    Article  CAS  PubMed  Google Scholar 

  11. Gui X, Yang Z, Li MD. Effect of cigarette smoke on gut microbiota: state of knowledge. Front Physiol. 2021;12: 673341.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Antinozzi M, Giffi M, Sini N, Galle F, Valeriani F, De Vito C, Liguori G, Romano Spica V, Cattaruzza MS. Cigarette smoking and human gut microbiota in healthy adults: a systematic review. Biomedicines. 2022;10(2):510.

  13. Hu X, Fan Y, Li H, Zhou R, Zhao X, Sun Y, Zhang S. Impacts of cigarette smoking status on metabolomic and gut microbiota profile in male patients with coronary artery disease: a multi-omics study. Front Cardiovasc Med. 2021;8: 766739.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yoon H, Lee DH, Lee JH, Kwon JE, Shin CM, Yang SJ, Park SH, Lee JH, Kang SW, Lee JS, et al. Characteristics of the gut microbiome of healthy young male soldiers in South Korea: the effects of smoking. Gut Liver. 2021;15(2):243–52.

    Article  PubMed  Google Scholar 

  15. Jung Y, Tagele SB, Son H, Ibal JC, Kerfahi D, Yun H, Lee B, Park CY, Kim ES, Kim SJ, et al. Modulation of gut microbiota in Korean navy trainees following a healthy lifestyle change. Microorganisms. 2020;8(9):1265.

  16. Yang HT, Xiu WJ, Liu JK, Yang Y, Zhang YJ, Zheng YY, Wu TT, Hou XG, Wu CX, Ma YT, et al. Characteristics of the intestinal microorganisms in middle-aged and elderly patients: effects of smoking. ACS Omega. 2022;7(2):1628–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ishaq HM, Shahzad M, Wu X, Ma C, Xu J. Molecular characterization of fecal microbiota of healthy Chinese tobacco smoker subjects in Shaanxi Province, Xi’an China. J Ayub Med Coll Abbottabad. 2017;29(1):3–7.

    PubMed  Google Scholar 

  18. Tomoda K, Kubo K, Asahara T, Andoh A, Nomoto K, Nishii Y, Yamamoto Y, Yoshikawa M, Kimura H. Cigarette smoke decreases organic acids levels and population of bifidobacterium in the caecum of rats. J Toxicol Sci. 2011;36(3):261–6.

    Article  PubMed  Google Scholar 

  19. Hu J, Wei T, Sun S, Zhao A, Xu C. Effects of cigarette smoke condensate on the production and characterization of exopolysaccharides by Bifidobacterium. An Acad Bras Cienc. 2015;87(2):997–1005.

    Article  CAS  PubMed  Google Scholar 

  20. Ridaura V, Belkaid Y. Gut microbiota: the link to your second brain. Cell. 2015;161(2):193–4.

    Article  CAS  PubMed  Google Scholar 

  21. Cryan JF, O’Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, Codagnone MG, Cussotto S, Fulling C, Golubeva AV, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877–2013.

    Article  CAS  PubMed  Google Scholar 

  22. Yang Z, Li J, Gui X, Shi X, Bao Z, Han H, Li MD. Updated review of research on the gut microbiota and their relation to depression in animals and human beings. Mol Psychiatry. 2020;25(11):2759–72.

    Article  PubMed  Google Scholar 

  23. Liu X, Tang S, Zhong H, Tong X, Jie Z, Ding Q, Wang D, Guo R, Xiao L, Xu X, et al. A genome-wide association study for gut metagenome in Chinese adults illuminates complex diseases. Cell Discov. 2021;7(1):9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Spinella M. Correlations between orbitofrontal dysfunction and tobacco smoking. Addict Biol. 2002;7(4):381–4.

    Article  PubMed  Google Scholar 

  25. Hayashi T, Ko JH, Strafella AP, Dagher A. Dorsolateral prefrontal and orbitofrontal cortex interactions during self-control of cigarette craving. Proc Natl Acad Sci U S A. 2013;110(11):4422–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Meckel KR, Kiraly DD. A potential role for the gut microbiome in substance use disorders. Psychopharmacology. 2019;236(5):1513–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kiraly DD, Walker DM, Calipari ES, Labonte B, Issler O, Pena CJ, Ribeiro EA, Russo SJ, Nestler EJ. Alterations of the host microbiome affect behavioral responses to cocaine. Sci Rep. 2016;6:35455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Lee K, Vuong HE, Nusbaum DJ, Hsiao EY, Evans CJ, Taylor AMW. The gut microbiota mediates reward and sensory responses associated with regimen-selective morphine dependence. Neuropsychopharmacology. 2018;43(13):2606–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Chakrabarti A, Geurts L, Hoyles L, Iozzo P, Kraneveld AD, La Fata G, Miani M, Patterson E, Pot B, Shortt C, et al. The microbiota-gut-brain axis: pathways to better brain health. Perspectives on what we know, what we need to investigate and how to put knowledge into practice. Cell Mol Life Sci. 2022;79(2):80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, Datta G, Davila-Velderrain J, McGuire D, Tian C, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019;51(2):237–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, Demirkan A, Le Roy CI, Raygoza Garay JA, Finnicum CT, Liu X, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. 2021;53(2):156–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, Demirkan A, Le Roy CI, Raygoza Garay JA, Finnicum CT, Liu X et al: MiBioGen. 2021.

  33. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, Datta G, Davila-Velderrain J, McGuire D, Tian C et al: Data related to association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. 2019.

  34. Wootton RE, Richmond RC, Stuijfzand BG, Lawn RB, Sallis HM, Taylor GMJ, Hemani G, Jones HJ, Zammit S, Davey Smith G, et al. Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. Psychol Med. 2020;50(14):2435–43.

    Article  PubMed  Google Scholar 

  35. Richmond. R, Stujifzand. B, Lawn. R, Sallis. H, Taylor. G, Hemani. G, Jones. H, Zammit. S, Smith. GD: Genome-wide association study of lifetime smoking index in a sample of 462,690 individuals from the UK Biobank. 2019.

  36. Kondziella D. The top 5 neurotransmitters from a clinical neurologist’s perspective. Neurochem Res. 2017;42(6):1767–71.

    Article  CAS  PubMed  Google Scholar 

  37. Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron. 2019;102(1):75–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kaur H, Golovko S, Golovko MY, Singh S, Darland DC, Combs CK. Effects of Probiotic Supplementation on Short Chain Fatty Acids in the AppNL-G-F Mouse Model of Alzheimer’s Disease. J Alzheimers Dis. 2020;76(3):1083–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Fernstrom JD. Dietary precursors and brain neurotransmitter formation. Annu Rev Med. 1981;32:413–25.

    Article  CAS  PubMed  Google Scholar 

  40. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, Arnold M, Erte I, Forgetta V, Yang TP, et al. An atlas of genetic influences on human blood metabolites. Nat Genet. 2014;46(6):543–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, Arnold M, Erte I, Forgetta V, Yang TP et al: An atlas of genetic influences on human blood metabolites. 2014.

  42. Tran SM, Mohajeri MH. The role of gut bacterial metabolites in brain development, aging and disease. Nutrients. 2021;13(3):732.

  43. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019;16(8):461–78.

    Article  PubMed  Google Scholar 

  44. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, Timpson NJ, Higgins JPT, Dimou N, Langenberg C, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ. 2021;375: n2233.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362: k601.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658–65.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Xue H, Shen X, Pan W. Constrained maximum likelihood-based Mendelian randomization robust to both correlated and uncorrelated pleiotropic effects. Am J Hum Genet. 2021;108(7):1251–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304–14.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377–89.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.

  52. Qu Z, Zhang L, Hou R, Ma X, Yu J, Zhang W, Zhuang C. Exposure to a mixture of cigarette smoke carcinogens disturbs gut microbiota and influences metabolic homeostasis in A/J mice. Chem Biol Interact. 2021;344: 109496.

    Article  CAS  PubMed  Google Scholar 

  53. Nolan-Kenney R, Wu F, Hu J, Yang L, Kelly D, Li H, Jasmine F, Kibriya MG, Parvez F, Shaheen I, et al. The association between smoking and gut microbiome in Bangladesh. Nicotine Tob Res. 2020;22(8):1339–46.

    Article  CAS  PubMed  Google Scholar 

  54. Lin R, Zhang Y, Chen L, Qi Y, He J, Hu M, Zhang Y, Fan L, Yang T, Wang L, et al. The effects of cigarettes and alcohol on intestinal microbiota in healthy men. J Microbiol. 2020;58(11):926–37.

    Article  PubMed  Google Scholar 

  55. Sublette MG, Cross TL, Korcarz CE, Hansen KM, Murga-Garrido SM, Hazen SL, Wang Z, Oguss MK, Rey FE, Stein JH. Effects of smoking and smoking cessation on the intestinal microbiota. J Clin Med. 2020;9(9):2963.

  56. Northrup TF, Stotts AL, Suchting R, Matt GE, Quintana PJE, Khan AM, Green C, Klawans MR, Johnson M, Benowitz N, et al. Thirdhand smoke associations with the gut microbiomes of infants admitted to a neonatal intensive care unit: an observational study. Environ Res. 2021;197: 111180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. den Exter Blokland EA, Engels RC, Hale WW 3rd, Meeus W, Willemsen MC. Lifetime parental smoking history and cessation and early adolescent smoking behavior. Prev Med. 2004;38(3):359–68.

    Article  Google Scholar 

  58. Melchior M, Chastang JF, Mackinnon D, Galera C, Fombonne E. The intergenerational transmission of tobacco smoking–the role of parents’ long-term smoking trajectories. Drug Alcohol Depend. 2010;107(2–3):257–60.

    Article  PubMed  Google Scholar 

  59. Wen Z, He M, Peng C, Rao Y, Li J, Li Z, Du L, Li Y, Zhou M, Hui O, et al. Metabolomics and 16S rRNA gene sequencing analyses of changes in the intestinal flora and biomarkers induced by gastrodia-uncaria treatment in a rat model of chronic migraine. Front Pharmacol. 2019;10:1425.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Yu G, Xu C, Zhang D, Ju F, Ni Y. MetOrigin: Discriminating the origins of microbial metabolites for integrative analysis of the gut microbiome and metabolome. 2022;1(1):e10.

  61. Bercik P, Park AJ, Sinclair D, Khoshdel A, Lu J, Huang X, Deng Y, Blennerhassett PA, Fahnestock M, Moine D, et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil. 2011;23(12):1132–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Han W, Tellez LA, Perkins MH, Perez IO, Qu T, Ferreira J, Ferreira TL, Quinn D, Liu ZW, Gao XB, et al. A neural circuit for gut-induced reward. Cell. 2018;175(3):665-678 e623.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Tian P, Wang G, Zhao J, Zhang H, Chen W. Bifidobacterium with the role of 5-hydroxytryptophan synthesis regulation alleviates the symptom of depression and related microbiota dysbiosis. J Nutr Biochem. 2019;66:43–51.

    Article  CAS  PubMed  Google Scholar 

  64. Lu Y, Zhang Z, Tong L, Zhou X, Liang X, Yi H, Gong P, Liu T, Zhang L, Yang L, et al. Mechanisms underlying the promotion of 5-hydroxytryptamine secretion in enterochromaffin cells of constipation mice by Bifidobacterium and Lactobacillus. Neurogastroenterol Motil. 2021;33(7): e14082.

    Article  CAS  PubMed  Google Scholar 

  65. Kirby LG, Zeeb FD, Winstanley CA. Contributions of serotonin in addiction vulnerability. Neuropharmacology. 2011;61(3):421–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Duranti S, Ruiz L, Lugli GA, Tames H, Milani C, Mancabelli L, Mancino W, Longhi G, Carnevali L, Sgoifo A, et al. Bifidobacterium adolescentis as a key member of the human gut microbiota in the production of GABA. Sci Rep. 2020;10(1):14112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience. 2010;170(4):1179–88.

    Article  CAS  PubMed  Google Scholar 

  68. Cheng Y, Liu J, Ling Z. Short-chain fatty acids-producing probiotics: A novel source of psychobiotics. Crit Rev Food Sci Nutr. 2022;62(28):7929–59.

    Article  CAS  PubMed  Google Scholar 

  69. Kobayashi Y, Sugahara H, Shimada K, Mitsuyama E, Kuhara T, Yasuoka A, Kondo T, Abe K, Xiao JZ. Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease. Sci Rep. 2017;7(1):13510.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne). 2020;11:25.

    Article  PubMed  Google Scholar 

  71. Arentsen T, Khalid R, Qian Y, Diaz Heijtz R. Sex-dependent alterations in motor and anxiety-like behavior of aged bacterial peptidoglycan sensing molecule 2 knockout mice. Brain Behav Immun. 2018;67:345–54.

    Article  CAS  PubMed  Google Scholar 

  72. Arentsen T, Qian Y, Gkotzis S, Femenia T, Wang T, Udekwu K, Forssberg H, Diaz Heijtz R. The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain development and behavior. Mol Psychiatry. 2017;22(2):257–66.

    Article  CAS  PubMed  Google Scholar 

  73. Langdon KJ, Bakhshaie J, Lopez A, Tavakoli N, Garey L, Raines AM, Kauffman BY, Schmidt NB, Zvolensky MJ. Anxiety sensitivity physical and cognitive concerns in relation to smoking-oriented cognition: an examination among treatment-seeking adults who smoke. J Addict Med. 2018;12(3):212–9.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Jia X, Gao Z, Hu H. Microglia in depression: current perspectives. Sci China Life Sci. 2021;64(6):911–25.

    Article  CAS  PubMed  Google Scholar 

  75. Prusakowski MK, Shofer FS, Rhodes KV, Mills AM. Effect of depression and psychosocial stressors on cessation self-efficacy in mothers who smoke. Matern Child Health J. 2011;15(5):620–6.

    Article  PubMed  Google Scholar 

  76. Kometani T, Yoshino I, Miura N, Okazaki H, Ohba T, Takenaka T, Shoji F, Yano T, Maehara Y. Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway. Cancer Lett. 2009;278(1):27–33.

    Article  CAS  PubMed  Google Scholar 

  77. Wang H, Zhao JX, Hu N, Ren J, Du M, Zhu MJ. Side-stream smoking reduces intestinal inflammation and increases expression of tight junction proteins. World J Gastroenterol. 2012;18(18):2180–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010;34(3):J258-265.

    Article  CAS  PubMed  Google Scholar 

  79. Talukder MA, Johnson WM, Varadharaj S, Lian J, Kearns PN, El-Mahdy MA, Liu X, Zweier JL. Chronic cigarette smoking causes hypertension, increased oxidative stress, impaired NO bioavailability, endothelial dysfunction, and cardiac remodeling in mice. Am J Physiol Heart Circ Physiol. 2011;300(1):H388-396.

    Article  CAS  PubMed  Google Scholar 

  80. Liu X, Tong X, Zou Y, Lin X, Zhao H, Tian L, Jie Z, Wang Q, Zhang Z, Lu H, et al. Mendelian randomization analyses support causal relationships between blood metabolites and the gut microbiome. Nat Genet. 2022;54(1):52–61.

    Article  CAS  PubMed  Google Scholar 

Download references


The data analyzed in this study was provided by MiBioGen consortium, GSCAN consortium, UK Biobank, and Shin’s Lab. We gratefully acknowledge their contributing studies and the participants in the corresponding studies without whom this effort would not be possible.


This work was supported by Fundamental Research Funds from the Central Universities of Zhejiang University and the National Natural Sciences Foundation of China (82204118).

Author information

Authors and Affiliations



DZ, YJL, and YMZ were the major contributors in conceptualization. DZ, JYF, and YZ analyzed the data. RM, JST, JHZ, MCA, and NJC verified the correctness of the data. DZ, JYF, and YZ were major contributors in writing the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yimin Zhu, Yingjun Li or Dan Zhou.

Ethics declarations

Ethics approval and consent to participate

This research has been conducted using published studies and consortia providing publicly available summary statistics. All original studies have been approved by the corresponding ethical review board, and the participants have provided informed consent. In addition, no individual-level data was used in this study. Therefore, no new ethical review board approval was required.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Self-inspection results of STROBE-MR checklist of recommended items to address in reports of Mendelian randomization studies. Table S2. Self-inspection results of critical appraisal checklist proposed by Davies et al. for evaluating Mendelian randomization studies. Table S3. The MR results of causal links between gut microbiome and smoking phenotypes by using IVW method under two instrumental variable selection thresholds. Figure S1. Overview of the analytical plan and main findings. Figure S2. Scatter plot of associations between genetic variants and Actinobacteria[p] versus between genetic variants and Cigarettes Per Day. The slope of each line represents the causal effect estimate using the corresponding MR analysis model, and the intercept can be interpreted as an estimate of the average horizontal pleiotropic effect across the genetic variants. Figure S3. Forest plot of individual SNP estimates and summary estimates for the causal associations between Actinobacteria[p] abundance and Cigarettes Per Day. Figure S4. Leave-one-out plot to assess if a single SNP drives the causal association between Actinobacteria[p] abundance and Cigarettes Per Day. Figure S5. Funnel plot of MR estimation for the causal association between Actinobacteria[p] abundance and Cigarettes Per Day.

Additional file 2: Table S4.

All results of causal links between gut microbiome and smoking phenotypes. Table S5. Instrumental variables used in our study for univariate MR and multivariable MR, respectively.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fan, J., Zhou, Y., Meng, R. et al. Cross-talks between gut microbiota and tobacco smoking: a two-sample Mendelian randomization study. BMC Med 21, 163 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: